Efficacy and safety of purified botulinum toxin type A (Dysport®) for the treatment of benign essential blepharospasm: A randomized, placebo-controlled, phase II trial

Daniel Truong, Cynthia Comella, Hubert H. Fernandez, William G. Ondo

Research output: Contribution to journalArticle

55 Scopus citations

Abstract

The majority of studies on the effects of botulinum toxin in blepharospasm patients have been small or unblinded. Our large-scale, multicenter, randomized clinical trial on the efficacy and safety of botulinum toxin (Dysport®; 40, 80, and 120 units/eye) versus placebo in bilateral benign essential blepharospasm (BEB) supported the high efficacy and good safety profile of Dysport®, with improvement in functional impairment, reduced frequency and intensity of facial spasms, and fewer withdrawals through lack of efficacy in the active treatment group compared with controls. The best balance of sustained efficacy and favorable safety profile was provided by 80 units of Dysport®/eye in this study.

Original languageEnglish (US)
Pages (from-to)407-414
Number of pages8
JournalParkinsonism and Related Disorders
Volume14
Issue number5
DOIs
StatePublished - Jul 2008

Keywords

  • Blepharospasm
  • Botulinum toxin
  • Dysport
  • Dystonia

ASJC Scopus subject areas

  • Neurology
  • Geriatrics and Gerontology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Efficacy and safety of purified botulinum toxin type A (Dysport<sup>®</sup>) for the treatment of benign essential blepharospasm: A randomized, placebo-controlled, phase II trial'. Together they form a unique fingerprint.

Cite this